1.Changes of portal hemodynamics in patients with liver cirrhosis and its clinical value
Haifeng ZHAO ; Qinsheng WEN ; Yuxin HUANG ; Baishan ZHAO ; Haitang SONG ;
Journal of Medical Postgraduates 2003;0(10):-
Objectives:To investigate the changes of portal hemodynamics in patients with liver cirrhosis and its clinical value. Methods:Forty patients with liver cirrhosis and twenty healthy volunteers as controls were involved in this study.The max diameters,mean flow velocity,flow rate and congestion index(CI) of the portal vein trunks(PV) and splenic veins(SV) were detected by Color Doppler Ultrasound in all subjects. Results:The PV diameters(PVD), PVT flow rate(PVF), PVCI and SV diameter(SVD),SV flow rate(SVF),SVCI were significantly highter in patients than in controls( P
2.Retrospective multicenter nested case-control safety study of Ilaprazole sodium for injection
Jin LI ; Rende FANG ; Juan SONG ; Yongzhou ZHANG ; Fan ZHANG ; Qun ZHAO ; Suhua CAI ; Yi ZHANG ; Haitang HU ; Jianxiong DENG
China Pharmacy 2023;34(11):1379-1383
OBJECTIVE To understand the safety of Ilaprazole sodium for injection in clinical practice. METHODS From Jan. 1st 2019 to Feb. 29th 2020, the data of 3 926 valid hospitalized patients receiving Ilaprazole sodium for injection were collected prospectively from 5 third-level hospitals through CHPS, and the post-marketing safety analysis was performed by using retrospective multicenter single cohort study. At the same time, a nested case-control study (the ratio of trial group and control group was 1∶4) was used to confirm the baseline stability of this study cohort and the correlation between adverse reactions and Ilaprazole sodium for injection. RESULTS Among 3 926 patients, 3 patients experienced 5 adverse drug events after using Ilaprazole sodium for injection, with the incidence of 0.076%. There was no serious adverse event, and the occurrence time was 2 days after medication; adverse drug events mainly include elevated liver function indicators (alanine transaminase, aspartate transaminase, total bilirubin), which were mild and untreated, and all adverse drug events were improved. The results of the nested case-control study showed that the trial group and the control group belonged to the same background baseline, and the occurrence of adverse drug events was more closely related to Ilaprazole sodium for injection. CONCLUSIONS The overall safety of Ilaprazole sodium for injection is relatively high, and the occurrence of adverse events is more related to it.